Section Arrow
ENSC.NASDAQ
- Ensysce Biosciences
(Financial Status)
Quotes are at least 15-min delayed:2024/05/29 05:34 EDT
Last
 0.575
+0.005 (+0.88%)
Day High 
0.595654 
Prev. Close
0.57 
1-M High
0.75 
Volume 
61.37K 
Bid
0.56
Ask
0.7
Day Low
0.562 
Open
0.58 
1-M Low
0.512 
Market Cap 
4.32M 
Currency USD 
P/E -- 
%Yield
10-SMA 0.62 
20-SMA 0.6 
50-SMA 0.67 
52-W High 2.64 
52-W Low 0.512 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.16/-0.87
Enterprise Value
4.46M
Balance Sheet
Book Value Per Share
0.49
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.6249-0.0362-5.48%-- 
SCPXScorpius Holdings0.1119+0.0067+6.37%-- 
INSMInsmed48.06+26.06+118.45%-- 
KTRAKintara Therapeutics0.188499+0.020499+12.20%-- 
NVAXNovavax15.515+0.015+0.10%-- 
Quotes are at least 15-min delayed:2024/05/29 05:34 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.